What is a stock summary page? Click here for an overview.
Business Description
EyePoint Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US30233G1004
Compare
Compare
Traded in other countries / regions
EYPT.USAPV3B.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2008-06-12Description
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 16.97 | |||||
| Equity-to-Asset | 0.8 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.17 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 0.25 | |||||
| Beneish M-Score | 10.51 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -15.7 | |||||
| 3-Year EBITDA Growth Rate | -9.6 | |||||
| 3-Year EPS without NRI Growth Rate | -3.3 | |||||
| 3-Year FCF Growth Rate | -9.8 | |||||
| 3-Year Book Growth Rate | -3.2 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.18 | |||||
| 9-Day RSI | 42.47 | |||||
| 14-Day RSI | 43.83 | |||||
| 3-1 Month Momentum % | -18.69 | |||||
| 6-1 Month Momentum % | -26.87 | |||||
| 12-1 Month Momentum % | -72.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.81 | |||||
| Quick Ratio | 7.77 | |||||
| Cash Ratio | 7.56 | |||||
| Days Inventory | 333.28 | |||||
| Days Sales Outstanding | 10.43 | |||||
| Days Payable | 923.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -26.3 | |||||
| Shareholder Yield % | -38.88 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 91.42 | |||||
| Operating Margin % | -337.06 | |||||
| Net Margin % | -302.43 | |||||
| FCF Margin % | -301.06 | |||||
| ROE % | -50.34 | |||||
| ROA % | -37.87 | |||||
| ROIC % | -224.96 | |||||
| 3-Year ROIIC % | -313.93 | |||||
| ROC (Joel Greenblatt) % | -595.67 | |||||
| ROCE % | -45.33 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 8.09 | |||||
| PB Ratio | 1.27 | |||||
| Price-to-Tangible-Book | 1.27 | |||||
| EV-to-EBIT | -0.61 | |||||
| EV-to-EBITDA | -0.62 | |||||
| EV-to-Revenue | 1.84 | |||||
| EV-to-Forward-Revenue | 3.25 | |||||
| EV-to-FCF | -0.61 | |||||
| Price-to-GF-Value | 1.16 | |||||
| Price-to-Median-PS-Value | 0.96 | |||||
| Price-to-Net-Current-Asset-Value | 1.42 | |||||
| Price-to-Net-Cash | 1.47 | |||||
| Earnings Yield (Greenblatt) % | -163.93 | |||||
| FCF Yield % | -30.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EYPT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
EyePoint Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 43.273 | ||
| EPS (TTM) ($) | -2.31 | ||
| Beta | 2.06 | ||
| 3-Year Sharpe Ratio | 0.38 | ||
| 3-Year Sortino Ratio | 1.22 | ||
| Volatility % | 77.07 | ||
| 14-Day RSI | 43.83 | ||
| 14-Day ATR ($) | 0.527956 | ||
| 20-Day SMA ($) | 6.4905 | ||
| 12-1 Month Momentum % | -72.52 | ||
| 52-Week Range ($) | 5.54 - 23.645 | ||
| Shares Outstanding (Mil) | 68.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
EyePoint Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
EyePoint Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
EyePoint Pharmaceuticals Inc Frequently Asked Questions
What is EyePoint Pharmaceuticals Inc(EYPT)'s stock price today?
The current price of EYPT is $6.24. The 52 week high of EYPT is $23.65 and 52 week low is $5.54.
When is next earnings date of EyePoint Pharmaceuticals Inc(EYPT)?
The next earnings date of EyePoint Pharmaceuticals Inc(EYPT) is 2025-05-08 Est..
Does EyePoint Pharmaceuticals Inc(EYPT) pay dividends? If so, how much?
EyePoint Pharmaceuticals Inc(EYPT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers